Acquisition by David Watson of 6122 shares of Argan at 50.3 subject to Rule 16b-3
| 1JK Stock | EUR 31.28 0.82 2.55% |
Roughly 61% of APELLIS PHARMACTDL's investor base is looking to short. The analysis of current outlook of investing in APELLIS PHARMACTDL 0001 suggests that many traders are alarmed regarding APELLIS PHARMACTDL's prospects. The current market sentiment, together with APELLIS PHARMACTDL's historical and current headlines, can help investors time the market. In addition, many technical investors use APELLIS PHARMACTDL 0001 stock news signals to limit their universe of possible portfolio assets.
APELLIS PHARMACTDL stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of APELLIS daily returns and investor perception about the current price of APELLIS PHARMACTDL 0001 as well as its diversification or hedging effects on your existing portfolios.
APELLIS |
Filed transaction by Argan Inc Director, Officer President And Ceo. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
APELLIS PHARMACTDL Fundamental Analysis
We analyze APELLIS PHARMACTDL's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of APELLIS PHARMACTDL using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of APELLIS PHARMACTDL based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
APELLIS PHARMACTDL is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
APELLIS PHARMACTDL 0001 Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with APELLIS PHARMACTDL stock to make a market-neutral strategy. Peer analysis of APELLIS PHARMACTDL could also be used in its relative valuation, which is a method of valuing APELLIS PHARMACTDL by comparing valuation metrics with similar companies.
Peers
APELLIS PHARMACTDL Related Equities
| AOX | Alstria Office | 0.26 | ||||
| CUW | COLUMBIA SPORTSWEAR | 1.16 | ||||
| D2V | PARKEN Sport | 1.73 | ||||
| 8D9 | SCIENCE IN | 3.33 | ||||
| SCG | SPORTING | 3.77 | ||||
| 5QV | CITY OFFICE | 6.54 |
Complementary Tools for APELLIS Stock analysis
When running APELLIS PHARMACTDL's price analysis, check to measure APELLIS PHARMACTDL's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy APELLIS PHARMACTDL is operating at the current time. Most of APELLIS PHARMACTDL's value examination focuses on studying past and present price action to predict the probability of APELLIS PHARMACTDL's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move APELLIS PHARMACTDL's price. Additionally, you may evaluate how the addition of APELLIS PHARMACTDL to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |